Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT-4101 in overweight/obese subjects with NASH
NCT04004325Phase 2Terminated
- Sponsor
- Forma Therapeutics, Inc.
- Start
- May 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of FT-4101 in Nonalcoholic steatohepatitis (NASH) (2 cohorts), sponsored by Forma Therapeutics, Inc. Primary endpoints: Treatment-emergent Adverse Events at 20 weeks, Clinically Significant Changes in Laboratory Values at 20 weeks and 13 more. Started May 2019; status: terminated.
02
Drugs
FT-4101
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04004325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004325.